Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...
She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...
Genetically predicted rheumatoid arthritis is causally associated with prostate cancer, according to study findings.
The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...
A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...
After re-staging patients, ideally with PSMA-PET, and performing a biopsy to confirm the recurrence and stratify them into risk categories, it is time to discuss local salvage treatment. Options ...
An emergency doctor has highlighted three “worrying” symptoms that could indicate a deadly cancer that kills around 12,000 ...
An emergency physician has pinpointed a trio of "worrying" symptoms that might signal a lethal cancer accountable for nearly ...
Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death ...
GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with ...
In the next in our series, GP Dr Roger Henderson debunks common myths about prostate cancer – and highlights some less ...